Promising Alzheimer’s drug results hailed as ‘major milestone’
By
Kimberly Bonvissuto
Sep 29, 2022
An investigational drug showing promise in reducing cognitive decline in early Alzheimer’s disease is being hailed as having potential to “change the course” of the disease.
Hypertension, type 2 diabetes contribute to brain changes in Puerto Rican seniors
Apr 01, 2022
A high prevalence of hypertension and type 2 diabetes was seen among the Puerto Rican cohort; those with both have deteriorating patterns in major white matter tracts.
51 percent of tweets about dementia contain stigma: study
By
Lois A. Bowers
Apr 13, 2017
Fifty-one percent of tweets by private users of Twitter accounts contain comments that are stigmatizing when they mention dementia or the people who have it, according to a recently published study.
High-tech ‘bike-helmet’ part of emerging field of light therapy for dementia, Alzheimer’s
By
Aaron Dorman
Nov 16, 2023
Light therapy is one way that seniors can both maintain and monitor their brain and cognitive function, one tech company co-founder says.
Brain imaging company teases tech that will analyze side effects of new dementia drugs
By
Aaron Dorman
Nov 28, 2023
AI-enabled brain imaging technology will be launched next year to evaluate the side effects of new Alzheimer’s and dementia drugs.
Argentum calls for continued industry self-regulation as association ramps up advocacy efforts
By
Kimberly Bonvissuto
Sep 14, 2021
PHOENIX—Argentum has spent the past 18 months elevating several priorities, with senior living industry advocacy rising to the top as a critical need during the pandemic amid changing federal and state...
Light and sound therapy may fend off memory and cognitive damage for chemo patients
By
Aaron Dorman
Mar 08, 2024
A combination of light and sound therapy may be able to counteract the problems in the brain caused by chemo, new research shows.
Is Alzheimer’s research about to go down a new path?
By
John O'Connor
May 07, 2019
By finding ways to prevent connection losses, the disease progression potentially could be delayed or even reversed, experts said.
Company can’t market cannabidiol products for Parkinson’s, Alzheimer’s, FDA and FTC say
By
Lois A. Bowers
Oct 23, 2019
A Florida company must stop marketing its unapproved cannabidiol products using unsubstantiated claims that the products treat Parkinson’s disease, Alzheimer’s disease and other conditions, the Food...
Recommendations to reduce disparities in dementia care due in 2021
By
Kimberly Bonvissuto
Dec 09, 2020
Final recommendations on ways to reduce disparities in dementia, which were developed during a stakeholder roundtable sponsored by the Milken Institute Alliance to Improve Dementia Care, will be released...